| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $163,843,002 ) (Continued on the next page) |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 000 | 2 | NIH | 1/5/2024 | $628,653 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 2 | NIH | 11/8/2023 | $127,781 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA253731 | Targeting Oncogenic Drivers in Cancer | 000 | 5 | NIH | 1/17/2024 | $93,150 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 1 | NIH | 1/16/2024 | $505,974 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AG080395 | Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | 001 | 2 | NIH | 5/6/2024 | $26,700 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AG080395 | Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | 000 | 2 | NIH | 12/11/2023 | $240,300 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 001 | 2 | NIH | 5/24/2024 | $4,784 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 000 | 2 | NIH | 1/22/2024 | $69,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA267065 | Harnessing the repetitive genome for cancer immunotherapy | 000 | 2 | NIH | 7/29/2024 | $268,752 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA289134 | MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer | 000 | 1 | NIH | 6/14/2024 | $450,429 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R50CA211399 | Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer | 000 | 9 | NIH | 8/19/2024 | $332,082 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA181217 | Metabolic and epigenetic dependencies in melanomas during metastasis and targeted-drug resistance | 001 | 10 | NIH | 4/16/2024 | $22,522 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA181217 | Metabolic and epigenetic dependencies in melanomas during metastasis and targeted-drug resistance | 000 | 10 | NIH | 3/15/2024 | $405,420 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 1 | NIH | 12/1/2023 | $445,000 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA294507 | Myeloma multidimensional precancer atlas | 000 | 1 | NIH | 9/18/2024 | $1,128,990 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA276701 | Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment | 000 | 2 | NIH | 8/9/2024 | $163,077 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R61CA278449 | New Chemical Tools for Covalent Drug Discovery | 000 | 1 | NIH | 1/30/2024 | $249,647 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 000 | 2 | NIH | 12/21/2023 | $365,314 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer | 000 | 59 | NIH | 11/22/2023 | $11,441,846 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | DP5OD029637 | Dissecting the interaction between DNA damage repair defects and the tumor microenvironment | 001 | 5 | NIH | 8/29/2024 | $1 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | DP5OD029637 | Dissecting the interaction between DNA damage repair defects and the tumor microenvironment | 001 | 5 | NIH | 8/29/2024 | $442,499 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA293092 | Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells | 000 | 1 | NIH | 7/25/2024 | $513,859 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer | 007 | 59 | NIH | 9/5/2024 | -$73,952 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 1 | NIH | 4/8/2024 | $206,067 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 002 | 3 | NIH | 4/16/2024 | $34,005 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer | 006 | 59 | NIH | 4/25/2024 | $221,854 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK124384 | The role of NCOA4-mediated ferritinophagy in iron homeostasis and ferroptosis | 000 | 5 | NIH | 5/24/2024 | $352,873 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24HG011451 | Generating a full-length reference transcriptome for human protein-coding genes | 000 | 3 | NIH | 7/16/2024 | $647,290 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 001 | 2 | NIH | 4/16/2024 | $20,295 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer | 005 | 59 | NIH | 4/16/2024 | $20,875 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer | 004 | 59 | NIH | 4/16/2024 | $1,271,315 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA222574 | Molecular origins and evolution to chemoresistance in germ cell tumors | 005 | 7 | NIH | 4/18/2024 | $12,282 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA222574 | Molecular origins and evolution to chemoresistance in germ cell tumors | 004 | 7 | NIH | 4/17/2024 | $20,608 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA222574 | Molecular origins and evolution to chemoresistance in germ cell tumors | 002 | 7 | NIH | 1/23/2024 | $370,947 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer | 002 | 59 | NIH | 1/26/2024 | $187,875 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA222574 | Molecular origins and evolution to chemoresistance in germ cell tumors | 003 | 7 | NIH | 1/24/2024 | $221,076 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA259623 | Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs | 000 | 5 | NIH | 3/11/2024 | $195,134 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 001 | 3 | NIH | 1/12/2024 | $612,114 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 000 | 26 | NIH | 11/16/2023 | $475,795 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI158488 | CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | 001 | 4 | NIH | 5/23/2024 | $44,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 001 | 26 | NIH | 4/16/2024 | $26,432 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 002 | 26 | NIH | 8/16/2024 | $0 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI158488 | CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | 000 | 4 | NIH | 3/7/2024 | $400,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA249185 | Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | 000 | 4 | NIH | 7/19/2024 | $385,461 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R50CA265182 | Molecular origins and evolution to treatment resistance in genitourinary cancers | 000 | 3 | NIH | 8/7/2024 | $330,413 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA272657 | Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer | 000 | 3 | NIH | 8/6/2024 | $411,213 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA262577 | Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies | 000 | 3 | NIH | 8/14/2024 | $640,260 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | NU58DP007911 | Supporting Young Breast Cancer Survivors, Metastatic Breast Cancer Patients, and their Families | 00 | 1 | CDC | 9/12/2024 | $460,000 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269574 | Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer | 002 | 3 | NIH | 4/17/2024 | $853,924 |
|
